Publications by authors named "Marc Engelhardt"

Claim this Profile
A
A QM-AI Approach for the Acceleration of Accurate Assessments of Halogen-π Interactions by Training Neural Networks.
Marc U Engelhardt, Finn Mier, Markus O Zimmermann, Frank M Boeckler

J Chem Inf Model· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the safety and effectiveness of isavuconazole for the treatment of serious fungal disease in children with a weakened immune system.
Antonio C Arrieta, Laura Kovanda, Marc Engelhardt, Mark Jones, Rodney Croos-Dabrera

Expert Rev Anti Infect Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.
Thomas L Holland, Andrew F Shorr, J Scott Overcash, Marc Engelhardt, Mark Jones

J Antimicrob Chemother· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of QM Methods for the Evaluation of Halogen-π Interactions for Large-Scale Data Generation.
Marc U Engelhardt, Markus O Zimmermann, Finn Mier, Frank M Boeckler

J Chem Theory Comput· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.
Juanita Suzanne Lopez, Simon Haefliger, Ruth Plummer, Paul M Clement, Thomas R Jeffry Evans, Marc Engelhardt

Cell Rep Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.
Andrew F Shorr, Mark E Jones, Silke Friedmann, Daniel Ionescu, Mikael Saulay, Marc Engelhardt

PLoS One· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Halogen Bonding on Water─A Drop in the Ocean?
Marc U Engelhardt, Markus O Zimmermann, Marcel Dammann, Jason Stahlecker, Antti Poso

J Chem Theory Comput· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial.
Heidi Segers, Jaime G Deville, William J Muller, Angela Manzanares, Amit Desai, Marc Engelhardt

Antimicrob Agents Chemother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
Matthias Holdhoff, Xiaobu Ye, Roy E Strowd, Burt Nabors, Tobias Walbert, Marc Engelhardt

Neurooncol Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53.
Theresa Klett, Martin Schwer, Larissa N Ernst, Marc U Engelhardt, Simon J Jaag

Drug Des Devel Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.
Andrea Necchi, Rodryg Ramlau, Alejandro Falcón González, Arvind Chaudhry, Tilman Todenhöfer, Marc Engelhardt

JNCI Cancer Spectr· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftobiprole for Staphylococcus aureus Bacteremia. Reply.
Thomas L Holland, Marc Engelhardt, Vance G Fowler

N Engl J Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftobiprole for Treatment of Complicated Bacteremia.
Thomas L Holland, Sara E Cosgrove, Sarah B Doernberg, Timothy C Jenkins, Nicholas A Turner, Marc Engelhardt

N Engl J Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Principles and Applications of CFX Moieties as Unconventional Halogen Bond Donors in Medicinal Chemistry, Chemical Biology, and Drug Discovery.
Sebastian Vaas, Markus O Zimmermann, Dieter Schollmeyer, Jason Stahlecker, Marc U Engelhardt

J Med Chem· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models.
Filippo Spriano, Luca Aresu, Luciano Cascione, Giorgia Risi, Alberto J Arribas, Marc Engelhardt

Am J Cancer Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Markus Joerger, Thomas Hundsberger, Simon Haefliger, Roger von Moos, Andreas F Hottinger, Marc Engelhardt

Invest New Drugs· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies.
Kamal Hamed, Marc Engelhardt, Laura L Kovanda, Jin Ju Huang, Jean Yan

Sci Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
Stephan Braun, Paul McSheehy, Karine Litherland, Phil McKernan, Nicole Forster-Gross, Marc Engelhardt

Expert Opin Investig Drugs· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
J Scott Overcash, Charles Kim, Richard Keech, Illia Gumenchuk, Borislav Ninov, Marc Engelhardt

Clin Infect Dis· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A analysis of two Phase III trials showing the efficacy and tolerability of ceftobiprole in East Asian patients.
Haihui Huang, Lei Gao, Marc Engelhardt, Mikael Saulay, Kamal Hamed

Future Microbiol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ceftobiprole in patients aged 65 years or older: a  analysis of three Phase III studies.
Tobias Welte, Thomas Wl Scheeren, J Scott Overcash, Mikael Saulay, Marc Engelhardt

Future Microbiol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
Rebecca Kristeleit, Jeffry Evans, L Rhoda Molife, Nina Tunariu, Heather Shaw, Marc Engelhardt

Br J Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.
Markus Joerger, Anastasios Stathis, Yannis Metaxas, Dagmar Hess, Mara Mantiero, Marc Engelhardt

Invest New Drugs· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftobiprole versus daptomycin in bacteremia: a novel protocol for a double-blind, Phase III trial.
Kamal Hamed, Marc Engelhardt, Mark E Jones, Mikael Saulay, Thomas L Holland

Future Microbiol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucormycosis in South America: A review of 143 reported cases.
Marcio Nucci, Marc Engelhardt, Kamal Hamed

Mycoses· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis